Agenus publishes seminal study on botensilimab's activity in treatment-resistant cancers

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced the publication of a seminal study in the prestigious cancer discovery, a journal of the american association for cancer research, detailing the novel mechanism of action and effectiveness of botensilimab, an investigational, novel multifunctional anti-ctla-4 antibody, in various treatment-resistant cancers. the paper, entitled “botensilimab,.
AGEN Ratings Summary
AGEN Quant Ranking